EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale

Mette Marie Rosenkilde, Jyothis Thomas George, Murielle M Véniant, Jens Juul Holst iD

Diabetes · 01.08.2025 · 74 (8) · 1334-1338

DOI: 10.2337/dbi24-0027 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, online erschienen am 16.06.2025. Verfasst von Mette Marie Rosenkilde und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular and Translational Pharmacology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Receptors, Gastrointestinal Hormone, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a prevalent disease that also contributes to the incidence and severity of many other chronic diseases and health conditions. Treatment approaches include lifestyle intervention, bariatric surgery, and pharmacological approaches, with glucagon-like peptide 1 (GLP-1) receptor agonists approved specifically for weight loss having changed the treatment landscape significantly in the last 5 years. Targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor may enhance the metabolic benefits of GLP-1 receptor agonism. These beneficial effects are seen with both GIP receptor antagonism and GIP receptor agonism, although the mechanisms underlying this apparent paradox remain unknown. Here, we summarize the physiologic, genetic, and clinical evidence for pursuing GIP receptor antagonism to achieve metabolic and weight benefits. Both global and central nervous system knockout of GIP receptors protects mice fed a high-fat diet from obesity and insulin resistance. Genome-wide association studies in humans support this notion, correlating lower BMI with GIP receptor genetic variants with reduced function. Pharmacologic approaches in mice and monkeys confirm that GIP receptor antagonism enhances GLP-1–induced weight reduction and other metabolic benefits, and a phase 1 study provides proof of principle that beneficial effects extend to humans. GIP receptor antagonism may represent an important new mechanism to expand the treatment options available to individuals living with obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Gastrointestinal HormoneObesityAnti-Obesity AgentsAnimalsHumansMiceInsulin ResistanceGastric Inhibitory Polypeptide

Substanzen

Receptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorGastric Inhibitory PolypeptideAnti-Obesity Agents

Autor:innen und Institutionen

  • Molecular and Translational Pharmacology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Amgen Office of the Chief Medical Officer, Amgen, Thousand Oaks, CA.
  • Amgen Research Department of Cardiometabolic Disorders, Amgen, Thousand Oaks, CA.
  • Endocrinology and Metabolism, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Jens Juul Holst

Zitieren

APA

Rosenkilde, M. M., George, J. T., Véniant, M. M., & Holst, J. J. (2025). GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale. Diabetes, 74(8), 1334-1338. https://doi.org/10.2337/dbi24-0027

Vancouver

Rosenkilde MM, George JT, Véniant MM, Holst JJ. GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale. Diabetes. 2025;74(8):1334-1338. doi:10.2337/dbi24-0027

BibTeX
@article{Rosenkilde2025,
  author = {Rosenkilde, Mette Marie and George, Jyothis Thomas and Véniant, Murielle M and Holst, Jens Juul},
  title = {GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale},
  journal = {Diabetes},
  year = {2025},
  volume = {74},
  number = {8},
  pages = {1334--1338},
  doi = {10.2337/dbi24-0027}
}
Kostenlos starten →